AKT1 and cancer: Recently, it has been suggested that patients presenting with advanced cancer showing p.His1047Arg mutation (exon 20) may be more sensitive to PI3K/AKT/mTOR pathway inhibitors [64], although preclinical and early clinical studies imply that KRAS and PIK3CA concurrent mutations may induce resistance to such inhibitors [64, 65].